ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1301

Prevalence, Clinical and Genetic Risk Factors, and Time to Cataract Development in Childhood-onset Systemic Lupus Erythematosus

Sirikarn Tangcheewinsirikul1, Zhaoyu Ding2, Nicholas Chan3, Daniela Dominguez3, Andrea Knight4, Deborah Levy1, Lawrence Ng5, Earl Silverman1, Ruud Verstegen1 and Linda Hiraki1, 1The Hospital for Sick Children, Toronto, ON, Canada, 2SickKids Research Institute, Toronto, ON, Canada, 3The Hospital for Sick Children, Toronto, Canada, 4Hospital for Sick Children, Toronto, ON, Canada, 5The Hospital for Sick Children, Toronto, Canada, Toronto, ON, Canada

Meeting: ACR Convergence 2025

Keywords: genetics, Outcome measures, Pediatric rheumatology, Systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, October 27, 2025

Title: (1272–1305) Pediatric Rheumatology – Clinical Poster II

Session Type: Poster Session B

Session Time: 10:30AM-12:30PM

Background/Purpose: Cataracts are a significant ocular complication in childhood-onset systemic lupus erythematosus (cSLE). This study aimed to assess the prevalence, time to cataract development, and clinical and genetic risk factors associated with cataracts in cSLE.

Methods: We conducted a cohort study of children and adolescents diagnosed and followed for cSLE until age 18 years at a tertiary lupus clinic from 1992 to 2023. Genotyping was performed using a multiethnic array, ancestry was genetically inferred and individual polygenic risk scores (PRS) for cataracts were calculated using PRSice. Demographic and clinical variables, including sex, age at SLE diagnosis, disease duration, SLE manifestations, and high-dose glucocorticoid (GC) exposure (defined as ≥2 mg/kg/day or ≥40 mg/day if >30 kg, for at least 30 days). Cataract was diagnosed by an ophthalmologist or optometrist and recorded as part of the Systemic Lupus International Collaborating Clinics Damage Index (SLICC-DI). Summary statistics compared demographic and clinical features between patients with and without cataracts. We completed time to cataract development analyses and estimated the association between clinical features and PRSs with cataract risk in logistic regression models (P< 0.05).

Results: Of 482 cSLE patients, 83% were female. The mean age at diagnosis was 13.1±3.1 years, and mean disease duration was 4.5±3.0 years. The cohort was primarily of European (28%) and East Asian (25%) ancestry, followed by South Asian (18%), Admixed American (17%), and African (12%). Lupus nephritis occurred in 42%, and 49% received high-dose GC.Cataracts were documented in 9% of patients after a mean follow-up of 4.2 years. Cataract prevalence was highest among East Asian (30%), Admixed American (26%), and South Asian (23%) patients but was not statistically significant. High dose GC exposure was associated with cataracts in both univariate and multivariable adjusted models (Table 1).Cataracts PRS was not associated with odds of cataracts in the univariate or models adjusted for sex, ethnicity and high-dose GC exposure.

Conclusion: In this multiethnic cSLE cohort, 9% developed cataracts within 4.2 years of follow-up. High-dose GC exposure significantly increased cataract risk. We did not observe a significant association between a cataracts-PRS and the odds of developing cataracts in children and adolescents with cSLE. Future studies will include participants with adult-onset SLE.

Supporting image 1Table 1. Association of cataracts PRS and cataracts in univariate and multivariable adjusted models.

Supporting image 2Figure 1. Time to first cataract event in cSLE (n=482).


Disclosures: S. Tangcheewinsirikul: None; Z. Ding: None; N. Chan: None; D. Dominguez: None; A. Knight: Pfizer, 6; D. Levy: AbbVie/Abbott, 5, AstraZeneca, 5, Bristol-Myers Squibb(BMS), 5, Roche, 5; L. Ng: None; E. Silverman: None; R. Verstegen: AbbVie/Abbott, 2; L. Hiraki: Janssen, 2, 5.

To cite this abstract in AMA style:

Tangcheewinsirikul S, Ding Z, Chan N, Dominguez D, Knight A, Levy D, Ng L, Silverman E, Verstegen R, Hiraki L. Prevalence, Clinical and Genetic Risk Factors, and Time to Cataract Development in Childhood-onset Systemic Lupus Erythematosus [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/prevalence-clinical-and-genetic-risk-factors-and-time-to-cataract-development-in-childhood-onset-systemic-lupus-erythematosus/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/prevalence-clinical-and-genetic-risk-factors-and-time-to-cataract-development-in-childhood-onset-systemic-lupus-erythematosus/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology